There is a newer version of the record available.

Published March 14, 2026 | Version v8

Genetically Instrumented CYP19A1 Whole Blood Expression and Autism Spectrum Disorder Risk: A Two-Sample Mendelian Randomization Study

  • 1. ROR icon Boston University

Description

This repository contains the analytic code, data outputs, and manuscript files for a two-sample Mendelian randomization study evaluating whether genetically predicted CYP19A1 (aromatase) whole blood expression is causally associated with autism spectrum disorder (ASD) risk.

Exposure: Three conditionally independent GTEx v8 whole blood cis-eQTL instruments (ENSG00000137869.14; GTEx Portal REST API v2). Outcome: iPSYCH-PGC ASD GWAS (Grove et al. 2019; ieu-a-1185; 18,382 cases, 27,969 controls).

Principal finding: The primary IVW estimate (OR = 1.131, 95% CI 1.002–1.277, p = 0.046) is not robust — it is absent in all six sensitivity analyses and driven by a sub-genome-wide significant instrument (rs75015950) with multi-gene eQTL effects at the chr15 locus. No genome-wide significant CYP19A1 cis-eQTLs were identified in any of 13 GTEx v8 brain tissues. This study establishes the feasibility constraints of current CYP19A1 expression instrumentation for ASD.

Files included: manuscript PDF, analytic Python scripts, mr_instruments.json, mr_results.json, phewas_summary.json, tissue_scan_results_complete.csv, requirements.txt.

Submitted to: BMC Medical Genomics (under review).
Reporting standard: STROBE-MR (Skrivankova et al. 2021, JAMA).

Files

CYP19A1_ASD_MR_Manuscript_v8.pdf

Files (1.1 MB)

Name Size
md5:11784cf96f6f7a16030944ad2ebd92f5
1.1 MB Preview Download

Additional details

Related works

Is supplement to
Software: https://github.com/julian-borges-md/frontier-research-lab (URL)
Is supplemented by
Journal article: 40307628 (PMID)
Reviews
Journal article: 10.1001/jama.2021.18236 (DOI)

Software